Dr. Reddy’s Laboratories Ltd (RDY)
Aurigene Oncology Limited maakt bemoedigende eerste resultaten bekend van eerste twee cohorten van fase 1-onderzoek naar AUR112, een orale remmer van MALT1, bij recidiverende/refractaire lymfoïde maligniteiten
Avadel Pharmaceuticals (AVDL)
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
Dr. Reddy’s Laboratories Ltd (RDY)
Aurigene Oncology Limited annuncia dati iniziali incoraggianti dalle prime due coorti dello studio di Fase 1 di AUR112, un inibitore orale a piccola molecola di MALT1, nei linfomi recidivanti/refrattari
Dr. Reddy’s Laboratories Ltd (RDY)
Aurigene Oncology Limited gibt vielversprechende erste Daten aus den ersten beiden Kohorten der Phase-1-Studie zu AUR112 bekannt, einem oral verabreichten niedermolekularen Inhibitor von MALT1, bei wieder auftretenden oder hartnäckigen...
Dr. Reddy’s Laboratories Ltd (RDY)
Aurigene Oncology Limited annonce des données initiales encourageantes provenant des deux premiers groupes de létude de phase 1 évaluant lAUR112, un inhibiteur oral à petites molécules de MALT1, pour les lymphopathies malignes...
Incyte Corporation (INCY)
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medtronic plc. (MDT)
Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures
ResMed Inc (RMD)
New SEC Form for ResMed Inc.
Masimo Corporation (MASI)
Masimo - Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth
Masimo Corporation (MASI)
Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth